The Patent Finder

Acadia Pharmaceuticals Inc.

Also on record
Records under this name other than the patents Acadia Pharmaceuticals Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 47 patents it holds.

Back to Acadia Pharmaceuticals Inc.

PatentTitleStatus Expires Confidence
US 11,370,755Compositions of Trofinetide
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 11,866,406Compositions of Trofinetide
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 10,653,629Single layer oral dose of neuro-attenuating ketamine
Surrendered on reissue
Surrendered on reissue Feb 24, 2026 · From the USPTO record
Surrendered on reissueSurrendered on reissue Feb 24, 2026From the USPTO record
US 7,713,995Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Term ended
Term ended Dec 27, 2025 · From the USPTO record
Term endedTerm ended Dec 27, 2025From the USPTO record
US 7,659,285Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Term ended
Term ended Nov 19, 2025 · From the USPTO record
Term endedTerm ended Nov 19, 2025From the USPTO record
US 7,923,564Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
Term ended
Ended no later than Sep 26, 2025 · From the USPTO record
Term endedEnded no later than Sep 26, 2025From the USPTO record
US 8,236,960Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
Term ended
Ended no later than Sep 26, 2025 · From the USPTO record
Term endedEnded no later than Sep 26, 2025From the USPTO record
US 9,670,209Muscarinic Agonists
Lapsed on the fee record
Ended Jun 6, 2025 · High confidence
Lapsed on the fee recordEnded Jun 6, 2025High confidence
US 7,994,193Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases
Term ended
Term ended Jan 15, 2024 · High confidence
Term endedTerm ended Jan 15, 2024High confidence
US 8,008,323Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Term ended
Ended no later than Jan 15, 2024 · From the USPTO record
Term endedEnded no later than Jan 15, 2024From the USPTO record
10 of 67 patents shown.
Pro members see all 67.
Pro members: see all 67 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited